Indeed, in their large-scale study aimed at identifying the prevalence of BRAF mutations among Chinese patients with lung adenocarcinoma, they found that the median relapse-free survival (RFS) of patients harboring either BRAF exon 11 or BRAF exon 15 was significantly longer than the RFS of NSCLC patients harboring other types of mutations, including Epidermal Growth Factor Receptor (EGFR), Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS), Anaplastic Lymphoma Kinase (ALK), Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2), or wild-type (47.8 vs. 21.5 months) [53]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.